(Q84968455)
Statements
Linagliptin monotherapy in type 2 diabetes patients for whom metformin is inappropriate: an 18-week randomized, double-blind, placebo-controlled phase III trial with a 34-week active-controlled extension (English)
M von Eynatten
A H Barnett
S Patel
R Harper
R Toorawa
S Thiemann